Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2

Journal of General Virology

Volumn 91, Issue 5, 2010, Pages 1335-1345

  Hatada, Makiko ^a   Yoshimura, Kazuhisa ^a   Harada, Shigeyoshi ^a   Kawanami, Yoko ^a   Shibata, Junji ^a   Matsushita, Shuzo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTI V3 NEUTRALIZING MONOCLONAL ANTIBODY; ARGININE; ISOLEUCINE; LEUCINE; LYSINE; NEUTRALIZING ANTIBODY; SERINE; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE INSERTION; GENE MUTATION; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LOSS OF FUNCTION MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; V2 GENE; VIRUS GENE; VIRUS REPLICATION; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODIES, NEUTRALIZING; GLYCOSYLATION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SERIAL PASSAGE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77951039586     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.017426-0     Document Type: Article

References (50)

1. Anastassopoulou, C. G., Ketas, T. J., Klasse, P. J. & Moore, J. P. (2009). Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A 106, 5318-5323.
2. Baba, M., Miyake, H., Wang, X., Okamoto, M. & Takashima, K. (2007). Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 51, 707-715. (Pubitemid 46185293)
3. Berro, R., Sanders, R. W., Lu, M., Klasse, P. J. & Moore, J. P. (2009). Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog 5, e1000548.
4. Bontjer, I., Land, A., Eggink, D., Verkade, E., Tuin, K., Baldwin, C., Pollakis, G., Paxton, W. A., Braakman, I. & other authors (2009). Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol 83, 368-383.
5. Bunnik, E. M., Pisas, L., van Nuenen, A. C. & Schuitemaker, H. (2008). Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 82, 7932-7941.
6. Cao, Y., Qin, L., Zhang, L., Safrit, J. & Ho, D. D. (1995). Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 332, 201-208.
7. Cutalo, J. M., Deterding, L. J. & Tomer, K. B. (2004). Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J Am Soc Mass Spectrom 15, 1545-1555. (Pubitemid 39433848)
8. Deeks, S. G., Schweighardt, B., Wrin, T., Galovich, J., Hoh, R., Sinclair, E., Hunt, P., McCune, J. M., Martin, J. N. & other authors (2006). Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 80, 6155-6164.
9. Eda, Y., Takizawa, M., Murakami, T., Maeda, H., Kimachi, K., Yonemura, H., Koyanagi, S., Shiosaki, K., Higuchi, H. & other authors (2006). Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 80, 5552-5562.
10. Frost, S. D., Wrin, T., Smith, D. M., Kosakovsky Pond, S. L., Liu, Y., Paxinos, E., Chappey, C., Galovich, J., Beauchaine, J. & other authors (2005). Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 102, 18514-18519. (Pubitemid 43011257)
11. Gartner, S., Markovits, P., Markovitz, D. M., Kaplan, M. H., Gallo, R. C. & Popovic, M. (1986). The role of mononuclear phagocytes in HTLVIII/ LAV infection. Science 233, 215-219. (Pubitemid 16008118)
12. Gorny, M. K., Revesz, K., Williams, C., Volsky, B., Louder, M. K., Anyangwe, C. A., Krachmarov, C., Kayman, S. C., Pinter, A. & other authors (2004). The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 78, 2394-2404.
13. Guex, N., Diemand, A. & Peitsch, M. C. (1999). Protein modelling for all. Trends Biochem Sci 24, 364-367.
14. Hope, T. J., Huang, X. J., McDonald, D. & Parslow, T. G. (1990). Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif. Proc Natl Acad Sci U S A 87, 7787-7791. (Pubitemid 20341802)
15. Hwang, S. S., Boyle, T. J., Lyerly, H. K. & Cullen, B. R. (1991). Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253, 71-74.
16. Johnson, W. E. & Desrosiers, R. C. (2002). Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med 53, 499-518.
17. Joos, B., Trkola, A., Kuster, H., Aceto, L., Fischer, M., Stiegler, G., Armbruster, C., Vcelar, B., Katinger, H. & Gunthard, H. F. (2006). Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother 50, 1773-1779.
18. Krachmarov, C., Pinter, A., Honnen, W. J., Gorny, M. K., Nyambi, P. N., Zolla-Pazner, S. & Kayman, S. C. (2005). Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade A and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 79, 780-790. (Pubitemid 40053861)
19. Kuhmann, S. E., Pugach, P., Kunstman, K. J., Taylor, J., Stanfield, R. L., Snyder, A., Strizki, J. M., Riley, J., Baroudy, B. M. & other authors (2004). Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 78, 2790-2807.
20. Kwong, P. D., Doyle, M. L., Casper, D. J., Cicala, C., Leavitt, S. A., Majeed, S., Steenbeke, T. D., Venturi, M., Chaiken, I. & other authors (2002). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682. (Pubitemid 36764500)
21. Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P. & other authors (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79, 10108-10125.
22. Mahalanabis, M., Jayaraman, P., Miura, T., Pereyra, F., Chester, E. M., Richardson, B., Walker, B. & Haigwood, N. L. (2009). Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 83, 662-672.
23. Manrique, A., Rusert, P., Joos, B., Fischer, M., Kuster, H., Leemann, C., Niederost, B., Weber, R., Stiegler, G. & other authors (2007). In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 81, 8793-8808.
24. Marozsan, A. J., Kuhmann, S. E., Morgan, T., Herrera, C., Rivera- Troche, E., Xu, S., Baroudy, B. M., Strizki, J. & Moore, J. P. (2005). Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338, 182-199. (Pubitemid 40835936)
25. Masuda, T., Matsushita, S., Kuroda, M. J., Kannagi, M., Takatsuki, K. & Harada, S. (1990). Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region. J Immunol 145, 3240-3246.
26. McCaffrey, R. A., Saunders, C., Hensel, M. & Stamatatos, L. (2004). N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 78, 3279-3295. (Pubitemid 38568268)
27. Montefiori, D. C., Hill, T. S., Vo, H. T., Walker, B. D. & Rosenberg, E. S. (2001). Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 75, 10200-10207.
28. Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., III, Burton, D. R. & Ho, D. D. (1995). Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69, 101-109. (Pubitemid 24378783)
29. Nabatov, A. A., Pollakis, G., Linnemann, T., Kliphius, A., Chalaby, M. I. & Paxton, W. A. (2004). Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/ CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 78, 524-530. (Pubitemid 37549764)
30. Ogert, R. A., Wojcik, L., Buontempo, C., Ba, L., Buontempo, P., Ralston, R., Strizki, J. & Howe, J. A. (2008). Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373, 387-399.
31. Park, E. J., Vujcic, L. K., Anand, R., Theodore, T. S. & Quinnan, G. V., Jr (1998). Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J Virol 72, 7099-7107.
32. Pinter, A., Honnen, W. J., He, Y., Gorny, M. K., Zolla-Pazner, S. & Kayman, S. C. (2004). The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78, 5205-5215. (Pubitemid 38581472)
33. Pinter, A., Honnen, W. J., D'Agostino, P., Gorny, M. K., Zolla-Pazner, S. & Kayman, S. C. (2005). The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J Virol 79, 6909-6917. (Pubitemid 40677322)
34. Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B. & Kabat, D. (1998). Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72, 2855-2864. (Pubitemid 28175522)
35. Pugach, P., Kuhmann, S. E., Taylor, J., Marozsan, A. J., Snyder, A., Ketas, T., Wolinsky, S. M., Korber, B. T. & Moore, J. P. (2004). The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 321, 8-22. (Pubitemid 38368098)
36. Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100, 4144-4149. (Pubitemid 36418171)
37. Sagar, M., Wu, X., Lee, S. & Overbaugh, J. (2006). Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80, 9586-9598. (Pubitemid 44435633)
38. Saunders, C. J., McCaffrey, R. A., Zharkikh, I., Kraft, Z., Malenbaum, S. E., Burke, B., Cheng-Mayer, C. & Stamatatos, L. (2005). The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol 79, 9069-9080. (Pubitemid 40934818)
39. Shibata, J., Yoshimura, K., Honda, A., Koito, A., Murakami, T. & Matsushita, S. (2007). Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J Virol 81, 3757-3768. (Pubitemid 46586873)
40. Sullivan, N., Thali, M., Furman, C., Ho, D. D. & Sodroski, J. (1993). Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol 67, 3674-3679. (Pubitemid 23143755)
41. Trkola, A., Kuster, H., Rusert, P., Joos, B., Fischer, M., Leemann, C., Manrique, A., Huber, M., Rehr, M. & other authors (2005). Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11, 615-622. (Pubitemid 40868301)
42. Trkola, A., Kuster, H., Rusert, P., von Wyl, V., Leemann, C., Weber, R., Stiegler, G., Katinger, H., Joos, B. & Gunthard, H. F. (2008). In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 82, 1591-1599.
43. Wang, F. X., Kimura, T., Nishihara, K., Yoshimura, K., Koito, A. & Matsushita, S. (2002). Emergence of autologous neutralizationresistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy. J Infect Dis 185, 608-617. (Pubitemid 34171465)
44. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M. & Kappes, J. C. (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46, 1896-1905. (Pubitemid 34535213)
45. Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M. & other authors (2003). Antibody neutralization and escape by HIV-1. Nature 422, 307-312.
46. Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G. & Perros, M. (2007). Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81, 2359-2371. (Pubitemid 46303353)
47. Yoshimura, K., Shibata, J., Kimura, T., Honda, A., Maeda, Y., Koito, A., Murakami, T., Mitsuya, H. & Matsushita, S. (2006). Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 20, 2065-2073. (Pubitemid 44611059)
48. Yusa, K., Maeda, Y., Fujioka, A., Monde, K. & Harada, S. (2005). Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J Biol Chem 280, 30083-30090. (Pubitemid 41216184)
49. Zhu, X., Borchers, C., Bienstock, R. J. & Tomer, K. B. (2000). Mass spectrometric characterization of the glycosylation pattern of HIVgp120 expressed in CHO cells. Biochemistry 39, 11194-11204.
50. Zolla-Pazner, S. (2004). Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4, 199-210.